rejuvant life tabs

Longevity biotech’s mitochondrial therapy enters IND

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

Longevity biotech firm CohBar nominates CB5138 analog as lead clinical candidate for idiopathic pulmonary fibrosis and other fibrotic diseases.

CohBar, a clinical-stage longevity biotech developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement into Investigational New Drug (IND)-enabling activities.

Longevity.Technology: IPF is a chronic, progressive, debilitating and usually fatal interstitial lung disease that affects approximately 100,000 people in the US alone. An orphan disease, IPF results in fibrotic scarring of the lungs, which is chronic, progressive, debilitating and usually fatal. There is currently no treatment that can stop or reverse the scarring of the lung and early detection of disease is key to slowing progression.

Mitochondria based therapeutics is an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders (Drs Pinchas Cohen and Nir Barzilai) of a novel group of naturally-occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs.

CB5138-3 is a CB5138 Analog, a novel class of molecules derived from a natural, mitochondrially encoded peptide source discovered by CohBar, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.

“Nominating our second clinical candidate is an exciting milestone for CohBar and provides additional confirmation of the potential of our novel discovery platform for mitochondria based therapeutics,” stated Steven Engle, CohBar’s Chief Executive Officer.

CEO Steven Engle
CohBar’s CEO Steven Engle.

“Our positive preclinical data in models of IPF support the further development of CB5138-3 as a potential antifibrotic and anti-inflammatory therapeutic for IPF, which remains an unmet medical need with few treatment options,” he continued. “Drugs currently approved for IPF can slow the progression of disease but can also cause significant side effects that limit their use. We look forward to the possibility of providing a new treatment option for this devastating disease and exploring the therapeutic potential of CB5138-3 as a treatment of other fibrotic diseases, including other interstitial lung diseases. Fibrotic diseases can affect any organ and are collectively responsible for 45% of deaths in the developed world.”

According to CohBar’s press release, multiple CB5138 Analogs demonstrated positive effects on all study outcomes in the therapeutic mouse model of IPF, including reduction of fibrosis, inflammation and collagen deposition. CohBar also showed enhanced effects for a CB5138 Analog in combination with the standard of care nintedanib (tyrosine protein kinase inhibitor), such as greater reduction in fibrosis, inflammation, collagen and pro-inflammatory cytokines compared with nintedanib alone.

Elevant

CohBar has now completed candidate screening activities and selected CB5138-3 as the lead CB5138 Analog for further development based on its preclinical efficacy data, preliminary safety profile, and drug-like properties.

CohBar will now move forward with IND-enabling activities for CB5138-3 with the goal of initiating clinical studies in 2022. In addition, the company is continuing to evaluate the efficacy of the CB5138 Analogs in models of other fibrotic diseases such as NASH, systemic sclerosis, and kidney fibrosis. Fibrosis can occur in the lungs, brain, liver, heart and other organs.

CohBar’s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programmes: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

Images courtesy of CohBar

2 COMMENTS

  1. MUST READ

    I suffered deeply with stage four sarcoidosis which progressed to idiopathic pulmonary fibrosis (IPF). I was hospitalized eighteen times in three years, mostly with flare ups and pneumonia. For me, the chronic widespread pain takes my breath away more than the disease itself. At times the pain is so severe I find it difficult to do anything. My life was gradually coming to an end, until I saw World Herbs Clinic on google during my research for alternative help for IPF.. I knew health is wealth thus I decided to give it a try, thank God I did. I got the Lungs disease formula four working days after placing an order. OMG I started noticing change in my breath after one month of taking the herbs formula, My IPF was completely reversed after THREE months of usage. Now i’m happy and free from this deadly disease. I recommend World Herbs Clinic for Lungs disease patients..

  2. Elevant

    I suffered deeply with stage four sarcoidosis which progressed to idiopathic pulmonary fibrosis (IPF). I was hospitalized eighteen times in three years, mostly with flare ups and pneumonia. For me, the chronic widespread pain takes my breath away more than the disease itself. At times the pain is so severe I find it difficult to do anything. My life was gradually coming to an end, until I saw World Herbs Clinic on google during my research for alternative help for IPF.. I knew health is wealth thus I decided to give it a try, thank God I did. I got the Lungs disease formula four working days after placing an order. OMG I started noticing change in my breath after one month of taking the herbs formula, My IPF was completely reversed after THREE months of usage. Now i’m happy and free from this deadly disease. I recommend World Herbs Clinic for Lungs disease patients..

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

New perspective in gerontology: epigenetic rejuvenation

Can biological age be set back by "making the clock tick backwards"? Scientists suggest that a partial phenotypic rejuvenation can be gained. Since the discovery...

BioAge licenses Amgen drug to treat muscle aging

Exclusive deal to develop and commercialise Amgen’s Phase 1 APJ agonist, after BioAge platform identifies its potential in promoting longevity and reducing symptoms of...

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...
Supps report ad middle